Redefining medical treatment in the management of unstable angina

American Journal of Medicine

Volumn 108, Issue 1, 2000, Pages 41-53

  Braunwald, Eugene ^a   Califf, Robert M ^a   Cannon, Christopher P ^a   Fox, Keith A A ^c   Fuster, Valentin ^d   Gibler, W Brian ^e   Harrington, Richard A ^b   King III, Spencer B ^f   Kleiman, Neil S ^g   Theroux, Pierre ^h   Topol, Eric J ⁱ   Van De Werf, Frans ^j   White, Harvey D ^k   Willerson, James T ^l  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY HOSPITAL   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j Leuven Coordinating Center   (Belgium)

^k GREEN LANE HOSPITAL   (New Zealand)

^l UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE MB; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; OROFIBAN; SIBRAFIBAN; THROMBIN; TIROFIBAN; TROPONIN C; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG; XEMILOFIBAN;

BLEEDING; BLOOD ANALYSIS; DISEASE CLASSIFICATION; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

ADMINISTRATION, ORAL; ANGINA, UNSTABLE; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; DIAGNOSIS, DIFFERENTIAL; ENOXAPARIN; GOVERNMENT AGENCIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MYOCARDIAL INFARCTION; NATIONAL INSTITUTES OF HEALTH (U.S.); PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES; RISK; TIME FACTORS; TROPONIN I; TROPONIN T; TYROSINE; UNITED STATES;

EID: 0033977734     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00416-7     Document Type: Review

References (96)

1. Detailed diagnoses, and procedures, National Hospital Discharge Survey. National Center for Health Statistics. Vital Health Stat 1998;1996:13:138.
2. Braunwald E. Unstable angina an etiologic approach to management . Circulation. 98:1998;2219-2222.
3. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction results of the TIMI IIIB trial . Circulation. 89:1994;1545-1556.
4. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. NEJM. 335:1996;775-782.
5. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. NEJM. 337:1997;447-452.
6. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. NEJM. 338:1998;1498-1505.
7. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. NEJM. 338:1998;1488-1497.
8. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. NEJM. 339:1998;436-443.
9. Russell M.W., Huse D.M., Drowns S., et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 81:1998;1110-1115.
10. Armstrong P.W., Fu Y., Chang W.C., et al. Acute coronary syndromes in the GUSTO-IIb trial prognostic insights and impact of recurrent ischemia . Circulation. 98:1998;1860-1868.
11. Wong P.S.C., El Gaylani N., Griffith K., et al. The clinical course of patients with acute myocardial infarction who are unsuitable for thrombolytic therapy because of the presenting electrocardiogram. Cor Art Dis. 9:1998;747-752.
12. Braunwald E., Jones R.H., Mark D.B., et al. Diagnosing and managing unstable angina. Circulation. 90:1994;613-622.
13. Agency for Health Care Policy, and Research. Braunwald E, Brown J, Brown L, et al. Diagnosing and managing unstable angina. Quick reference guide for clinicians, number 10. Rockville, MD: US Dept of Health and Human Services, 1994.
14. Braunwald E. Unstable angina a classification . Circulation. 80:1989;410-414.
15. van Miltenburg-van Zijl A.J., Simoons M.L., Veerhoek R.J., Bossuyt P.M. Incidence and follow-up of Braunwald subgoups in unstable angina pectoris. J Am Coll Cardiol. 25:1995;1286-1292.
16. van Domburg R.T., van Miltenburg-van Zijl A.J., Veerhoek R.J., Simoons M.L. Unstable angina good long-term outcome after a complicated early course . J Am Coll Cardiol. 31:1998;1534-1539.
17. Calvin J.E., Klein L.W., VandenBerg B.J., et al. Risk stratification in unstable angina. Prospective validation of the Braunwald classification. JAMA. 273:1995;136-141.
18. Ahmed W.H., Bittl J.A., Braunwald E. Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. Am J Cardiol. 72:1993;544-550.
19. Dangas G., Mehran R., Wallenstein S., et al. Correlation of angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol. 29:1997;519-525.
20. De Servi S., Arbustini E., Marsico F., et al. Correlation between clinical and morphologic findings in unstable angina. Am J Cardiol. 77:1996;128-132.
21. Rupprecht H.J., Sohn H.Y., Kearney P., et al. Clinical predictors of unstable coronary lesion morphology. Eur Heart J. 16:1995;1526-1534.
22. Owa M., Origasa H., Saito M. Predictive validity of the Braunwald classification of unstable angina for angiographic findings, short-term prognoses, and treatment selection. Angiology. 48:1997;663-671.
23. Califf R.M., Mark D.B., Harrell F.E. Jr, et al. Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. J Am Coll Cardiol. 11:1988;20-26.
24. Conti C.R. Pathophysiology and management of unstable angina. Clin Cardiol. 12:1989;616-617.
25. Wilcox I., Freedman S.B., McCredie R.J., et al. Risk of adverse outcome in patients admitted to the coronary care unit with suspected unstable angina pectoris. Am J Cardiol. 64:1989;845-848.
26. Murphy J.J., Connell P.A., Hampton J.R. Predictors of risk in patients with unstable angina admitted to a district general hospital. Br Heart J. 67:1992;395-401.
27. Bertolet B.D., Dinerman J., Hartke R. Jr, Conti C.R. Unstable angina relationship of clinical presentation, coronary artery pathology, and clinical outcome . Clin Cardiol. 16:1993;116-122.
28. Rizik D.G., Healy S., Margulis A., et al. A new clinical classification for hospital prognosis of unstable angina pectoris. Am J Cardiol. 75:1995;993-997.
29. Boden W.E., O'Rourke R.A., Crawford M.H., et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. NEJM. 338:1998;1785-1792.
30. Yusuf S., Flather M., Pogue J., et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet. 352:1998;507-514.
31. The FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicentre study. Lancet. 1999;354:708-715.
32. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Invasive versus conservative strategies in unstable angina and non-Q- wave myocardial infarction following treatment with tirofiban rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis in Myocardial Infarction . Am J Cardiol. 82:1998;731-736.
33. Lindahl B., Venge P., Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation. 93:1996;1651-1657.
34. Ohman E.M., Armstrong P.W., Christenson R.H., et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. NEJM. 335:1996;1333-1341.
35. Antman E.M., Tanasijevic M.J., Thompson B., et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. NEJM. 335:1996;1342-1349.
36. Hamm C.W., Goldmann B.U., Heeschen C., et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. NEJM. 337:1997;1648-1653.
37. Van de Werf F. Cardiac troponins in acute coronary syndromes. NEJM. 335:1996;1388-1389.
38. Bodor G.S., Porter S., Landt Y., Ladenson J.H. Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem. 38:1992;2203-2214.
39. Katus H.A., Looser S., Hallermayer K., et al. Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chem. 38:1992;386-393.
40. Hamm C.W., Ravkilde J., Gerhardt W., et al. The prognostic value of serum troponin T in unstable angina. NEJM. 327:1992;146-150.
41. Ravkilde J., Hárder M., Gerhardt W., et al. Diagnostic performance and prognostic value of serum troponin T in suspected acute myocardial infarction. Scand J Clin Lab Invest. 53:1993;677-685.
42. Ravkilde J., Nissen H., Hárder M., Thygesen K. Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction. Analysis of 28 months of follow-up in 196 patients. J Am Coll Cardiol. 25:1995;574-581.
43. Wu A.H., Abbas S.A., Green S., et al. Prognostic value of cardiac troponin T in unstable angina pectoris. Am J Cardiol. 76:1995;970-972.
44. Newby L.K., Christenson R.H., Ohman E.M., et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. Circulation. 98:1998;1853-1859.
45. Christenson R.H., Duh S.H., Newby L.K., et al. Cardiac troponin T, and cardiac troponin I relative values in short-term risk stratification of patients with acute coronary syndromes . Clin Chem. 44:1998;494-501.
46. Olatidoye A.G., Wu A.H., Feng Y.J., Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol. 81:1998;1405-1410.
47. Antman E.M., Sacks D.B., Rifai N., et al. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes Thrombolysis in Myocardial Infarction (TIMI) 11A substudy . J Am Coll Cardiol. 31:1998;326-330.
48. Hamm C.W., Heeschen C., Goldmann B., et al. Benefit of of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. NEJM. 340:1999;1623-1629.
49. Lindahl B., Venge P., Wallentin L. The FRISC experience with troponin T use as decision tool and comparison with other prognostic markers . Eur Heart J. 19:1998;N51-N58.
50. Hamm CW, Heeschen C, Goldmann B, et al. Troponin T predicts the benefit of abciximab in patients with unstable angina in the CAPTURE study. Eur Heart J. 1998;19(abstr suppl):117. Abstract.
51. de Beer F.C., Hind C.R., Fox K.M., et al. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 47:1982;239-243.
52. Berk B.C., Weintraub W.S., Alexander R.W. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 65:1990;168-172.
53. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. NEJM. 331:1994;417-424.
54. Haverkate F., Thompson S.G., Pyke S.D., et al. Production of C-reactive protein, and risk of coronary events in stable, and unstable angina. Lancet. 349:1997;462-466.
55. Toss H., Lindahl B., Siegbahn A., Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 96:1997;4204-4210.
56. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of, and in combination with troponin T in acute coronary syndromes. TIMI 11A substudy. J Am Coll Cardiol. 31:1998;1460-1465.
57. Oltrona L., Ardissino D., Merlini P.A., et al. C-reactive protein elevation, and early outcome in patients with unstable angina pectoris. Am J Cardiol. 80:1997;1002-1006.
58. Montalescot G., Philippe F., Ankri A., et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease beneficial effects of enoxaparin . Circulation. 98:1998;294-299.
59. Almony G.T., Lefkovits J., Topol E.J. Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol. 19:1996;357-365.
60. Theroux P., Waters D., Lam J., et al. Reactivation of unstable angina after the discontinuation of heparin. NEJM. 327:1992;141-145.
61. Weitz J.I. Low-molecular-weight heparins. NEJM. 337:1997;688-698.
62. Hirsh J. Low-molecular-weight heparin:a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation. 98:1998;1575-1582.
63. Weitz JI, Hirsh J. Overview of new developments in heparins, thrombin inhibitors, and other new and novel agents. In: Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker, 1997:77-86.
64. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study . Lancet. 349:1997;1429-1435.
65. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
66. Klein L.W., Wahid F., VandenBerg B.J., et al. Comparison of heparin therapy for 48 hours to >48 hours in unstable angina pectoris. Am J Cardiol. 79:1997;259-263.
67. Leizorovicz A. The FRAXIS study. XXth Congress of the European Society of Cardiology, Vienna, Austria, August 1998:25.
68. Cohen M, Bigonzi F, Le Iouer V, et al. One year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction). J Am Coll Cardiol 1998;31(suppl A):79A. Abstract.
69. Antman EM, McCabe CH, Premmereur J, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of Thrombolysis is Myocardial Infarction (TIMI) 11B Trial. Circulation. 1999;100:1593-1601.
70. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI 11B ESSENCE Meta-Analysis. Circulation. 1999;100:1602-1608.
71. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999;353:429-438.
72. Topol E.J. Toward a new frontier in myocardial reperfusion therapy emerging platelet preeminence . Circulation. 97:1998;211-218.
73. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
74. Harrington R.A., Kleiman N.S., Kottke-Marchant K., et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 76:1995;1222-1227.
75. Kereiakes D.J., Kleiman N.S., Ambrose J., et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 27:1996;536-542.
76. Tardiff B.E., Miller J.M., Harrington R.A., Tcheng J.E., Califf R.M. Integrilin synthetic peptides against the platelet glycoprotein IIb/IIIa receptor . Sasahara A.A., Loscalzo J. New Therapeutic Agents in Thrombosis and Thrombolysis. 1997;333-354 Marcel Dekker, New York.
77. Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIa receptor. In: Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker, 1997:355-365.
78. Coller B.S. Platelet GPIIb/IIIa antagonists. The first anti-integrin receptor therapeutics. J Clin Invest. 99:1997;1467-1471.
79. Simon D.I., Xu H., Ortlepp S., et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1, and blocks adhesion to fibrinogen, and ICAM-1. Arterioscler Thromb Vasc Biol. 17:1997;528-535.
80. Barr E, Snapinn SM, Sax FL, Theroux P. Improved long-term clinical outcomes in unstable angina-patients undergoing coronary angioplasty following therapy with tirofiban and heparin. J Am Coll Cardiol 1998;31(suppl A):55A. Abstract.
81. Hahn SS, Chae C, Giugliano R, et al. Troponin I levels in unstable angina/non-Q-wave myocardial infarction patients treated with tirofiban, a glycoprotein IIb/IIIa antagonist. J Am Coll Cardiol. 1998;31(suppl A):229A. Abstract.
82. McClure M.W., Berkowitz S.C., Sparapani R., et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience . Circulation. 99:1999;2892-2900.
83. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. NEJM. 330:1994;956-961.
84. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. NEJM. 336:1997;1689-1696.
85. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 352:1998;87-92.
86. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 349:1997;1422-1428.
87. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
88. Cannon C.P., McCabe C.H., Borzak S., et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome results of the TIMI 12 trial . Circulation. 97:1998;340-349.
89. Kereiakes D.J., Kleiman N.S., Ferguson J.J., et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban results of a multicenter, placebo-controlled, randomized trial . Circulation. 98:1998;1268-1278.
90. Ferguson JJ, Deedwania PC, Kereiakes DJ, et al. Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim pharmacodynamic results of the SOAR study. J Am Coll Cardiol 1998;31(suppl A):185A. Abstract.
91. Deedwania PC, Ferguson JJ, Kereiakes DJ, et al. Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim safety and tolerability results of the SOAR study. J Am Coll Cardiol 1998;31(suppl A):94A. Abstract.
92. Mascelli M.A., Worley S., Veriabo N.J., et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation. 96:1997;3860-3866.
93. Coller B.S. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation. 97:1998;5-9.
94. O'Neill W. Results of the EXCITE trial. 48th Annual Scientific Ses-sions, American College of Cardiology, New Orleans, Louisiana, March 7, 1999.
95. Cannon C. Results of the OPUS-TIMI 16 trial. 48th Annual Scientific Sessions, American College of Cardiology, New Orleans, Louisiana, March 10, 1999.
96. Topol E. Results of the SYMPHONY trial. XXI Congress of the European Society of Cardiology, Barcelona, September 1, 1999.